Insider buying last 90 days
No open-market insider purchases were filed for AORT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every AORT insider filing, plotted on the chart in Gekko.Open AORT in Gekko
NYSE: AORT
Artivion (AORT) Stock Analysis & Forecast
Oct 12 close
$21.79+0.53 (+2.5%)
Gekko Brief
Oct 12 closeArtivion closed at $21.79 on 12 October 2026, +2.5% on the day. The price sits below both the 50-day ($25.31) and 200-day ($30.94) moving averages, inside a 52-week range of $19.16 to $48.25. The GekkoIndex reads 66, in the Accumulation zone, down 2.7 points over five sessions. Gekko Fair Value is $31.57, so the price is 31% below it.
The next earnings report is due on 5 November 2026, 24 days away (after close). Over the last 8 reports the company beat the earnings estimate 4 times, with an average move of 12.4% across the report. Smart-money activity over the last 90 days includes 3 Congress purchases and 0 sales. Seasonally, the next 20 trading days from this point averaged +4% over the last 5 years, rising in 3 of them.
6 firms rate the stock: 6 buy, 0 hold and 0 sell, with a consensus target of $42.15. A typical daily move is about 4.5%, and a typical 20-day move about 7.7%. On the swing-trade checklist, 4 items read supportive and 2 read as a headwind (trend, earnings risk).
A plain summary of the figures as of the Oct 12, 2026 close.
Artivion price vs fair value
Close $21.79200-day averageGekko Fair Value $31.57
Artivion quick facts
- Market cap
- $1.06B
- P/E ratio
- —
- Forward P/E
- 35.3
- EPS, TTM
- −$0.07
- Revenue, TTM
- $471.5M
- Profit margin
- -0.7%
- Dividend yield
- —
- Beta
- 1.22
- Volume
- 436,615 avg 606,209
- 1-year return
- −46.0%
- Typical daily move
- ±4.5%
- Typical 20-day move
- ±7.7%
- 50-day average
- $25.31
- 200-day average
- $30.94
- Next earnings
- Nov 5 after close
- Shares outstanding
- 48.76M
Artivion swing-trade checklist
Artivion scores 4 supportive, 0 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive0 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $21.79 is below the 50-day ($25.31) and 200-day ($30.94) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
66, Accumulation
Reading 66 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
31.0% below
Price is 31% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 3 buys / 0 sales.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+4.0% on average
From this point in the calendar, the next 20 trading days averaged +4% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Artivion stock chart and price history
Artivion closed at $21.79 on Oct 12, 2026, −46.0% over the past year, inside a 52-week range of $19.16 to $48.25.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −13.1%
- 3 months
- −5.8%
- 6 months
- −43.5%
- 1 year
- −46.0%
The full AORT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open AORT in Gekko
Follow Artivion through every session
Put AORT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track AORT in GekkoFree for 7 days. No credit card required.
About Artivion
Artivion makes and supplies medical devices and preserved human tissue used mainly in heart and blood vessel surgery. Its best-known product is BioGlue, a surgical adhesive made from a bovine blood protein and a bonding agent, used in cardiac, vascular, neurological and pulmonary procedures. The company also provides tissue preservation services and valve repair patches, along with a line of stent graft systems built for different sections of the aorta and related arteries, plus heart valve devices sold under the On-X name.
Beyond its implants and grafts, Artivion sells hemostatic powders, synthetic vascular grafts, laser devices for angina treatment, specialty sutures and dissection stents, and it also performs carbon coating work for other device makers. Its customers are mainly physicians, hospitals and other care facilities, with particular use among cardiac, vascular, thoracic and general surgeons.
The company traces back to 1984 and took on the Artivion name in 2022, having previously been known as CryoLife. It is headquartered in Kennesaw, Georgia, and its shares are listed on the NYSE under the ticker AORT.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- artivion.com
Artivion GekkoIndex: the smart money zone
Artivion’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 66, in the Accumulation zone, down 2.7 points over five sessions.
66Accumulation
Down 2.7 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 49 | −1.4% | −2.3% | ||
| Accumulation (current zone) | 180 | −0.7% | +1.8% | ||
| Neutral | 393 | +1.1% | +2.7% | ||
| Distribution | 53 | +0.3% | −0.4% | ||
| Selling | 7 | Too few readings yet | |||
Average AORT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the AORT price, zone by zone.Track AORT in Gekko
Is Artivion stock overvalued? Gekko Fair Value
Artivion trades 31.0% below Gekko Fair Value of $31.57, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Artivion shares are worth, recalculated every trading day.
$31.57
Gekko Fair Value, Oct 10, 2026
31.0% Undervalued
At the end of Aug 2026 the price was 25.8% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open AORT in Gekko
Artivion insider and Congress trading
No open-market insider purchases were filed for Artivion, and members of Congress disclosed 3 purchases and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
3trades disclosed: 3 purchases and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Gilbert Cisneros House, CA, purchase | $1,001 - $15,000 | Sep 11 traded Aug 20 |
| Gilbert Ray Cisneros House, CA, purchase | $1,001 - $15,000 | Sep 7 traded Jul 16 |
| Gilbert Ray Cisneros House, CA, purchase | $1,001 - $15,000 | Sep 7 traded Jul 15 |
From congressional disclosures, which report amounts as ranges.
Buybacks
Artivion has been buying back its own shares.
- Bought back, quarter ended Dec 31, 2023
- $4K
- As a share of market cap
- 0.00%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold AORT.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Artivion earnings: next date and track record
Artivion reports on Nov 5, 2026, after the close (24 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected after the close, 24 days away
- EPS estimate
- −$0.06
- Revenue estimate
- $120.9M
4 of 8reports beat the EPS estimate
±12.4%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- Artivion reported Q2 2026 constant currency revenue growth of 9% and adjusted EBITDA growth of 7% year-over-year. On-X revenues surged 18% and stent grafts grew 12% on a constant currency basis. Key milestones include FDA PMA approval for AMDS hybrid prosthesis and completion of the Endospan acquisition, adding the NEXUS Aortic Arch Stent Graft System to create a complete three-pronged aortic arch portfolio.
- Guidance
- Full U.S. commercial launch of NEXUS system targeted for January 2027, addressing an approximately $100 million chronic aortic dissection market. Management expects AMDS set sales to accelerate following PMA approval, which eliminates the IRB review process barrier for new accounts.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.28 est $0.00 | $125.8M est $120.0M | +3.6% |
| May 7, 2026 | $0.03 est $0.06 | $116.3M est $115.7M | −26.8% |
| Feb 12, 2026 | $0.17 est $0.06 | $116.0M est $116.5M | −8.7% |
| Nov 6, 2025 | $0.16 est $0.14 | $113.4M est $116.4M | −3.5% |
| Aug 7, 2025 | $0.24 est $0.11 | $113.0M est $107.4M | +26.9% |
| May 5, 2025 | $0.06 est $0.12 | $98.98M est $108.5M | +17.5% |
| Feb 24, 2025 | −$0.39 est −$0.01 | $97.31M est $100.9M | −9.6% |
| Nov 7, 2024 | $0.12 est $0.10 | $95.78M est $101.2M | −2.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Artivion stock forecast and analyst price targets
Analysts’ average 12-month price target for Artivion is $42.15, +93.4% from the last close, from 6 firms rating the stock in the last 90 days.
$42.15consensus 12-month target, +93.4% from the last close
Now $21.79Avg $42.15
Low $38High $45
Each firm’s latest rating in the last 90 days: 6 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 18 | Canaccord Genuity | $40 | +83.6% |
| Aug 13 | Canaccord Genuity | $39 | +79.0% |
| Aug 7 | Stifel Nicolaus | $45 | +106.5% |
| Aug 7 | Ladenburg Thalmann & Co. | $39.20 | +79.9% |
| Aug 7 | Lake Street | $45 | +106.5% |
+1.8%average 20-day move after past Accumulation readings
+4.0%average move over the next 20 trading days in the last 5 years
±4.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Artivion seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Artivion averaged +4.0% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.7% | 2 of 5 |
| Next 10 trading days | −2.8% | 2 of 5 |
| Next 15 trading days | −0.7% | 2 of 5 |
| Next 20 trading days | +4.0% | 3 of 5 |
| Next 30 trading days | +4.2% | 4 of 5 |
For scale, AORT’s typical 20-trading-day move in either direction is about 7.7%.
Artivion market cap and key statistics
Artivion’s market cap is $1.06B and revenue of $471.5M over the last twelve months.
Valuation
- Market cap
- $1.06B
- Forward P/E
- 35.3
- EPS, TTM
- −$0.07
- Gekko Fair Value
- $31.57
Trading
- Volume
- 436,615
- Avg volume, 20 days
- 606,209
- 52-week high
- $48.25
- 52-week low
- $19.16
- Shares outstanding
- 48.76M
Financials
- Revenue, TTM
- $471.5M
- Profit margin
- -0.7%
- Return on equity
- -0.7%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.22
- Typical daily move
- ±4.5%
- Typical 20-day move
- ±7.7%
Artivion stock news this week
2 headlines about Artivion from the past week, newest first, each linking to the publisher.
- Transcript: Artivion Q2 2026 Earnings Conference CallBenzinga, Oct 12
- Artivion, Inc. (AORT) Stock ForecastsYahoo! Finance Canada, Oct 11
Artivion peers
Artivion’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
Artivion stock FAQ
What is Artivion’s market cap?
Artivion’s market cap is $1.06B at the Oct 12, 2026 close of $21.79, with 48.76M shares outstanding.
What is the Artivion stock forecast?
The consensus analyst 12-month price target for Artivion is $42.15, +93.4% from the last close. Of the 6 firms that rated the stock in the last 90 days, 6 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Artivion stock overvalued or undervalued?
On Gekko’s estimate Artivion is undervalued: the Oct 12, 2026 close of $21.79 is 31.0% below Gekko Fair Value of $31.57. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Artivion report earnings next?
Artivion is expected to report on Nov 5, 2026, after the market closes (24 days away). Analysts expect earnings of −$0.06 per share on revenue of $120.9M. Artivion beat the earnings estimate in 4 of its last 8 reports, moving 12.4% on average across the report.
What is Artivion’s 52-week high and low?
Artivion’s 52-week high is $48.25 and its 52-week low is $19.16; it closed at $21.79 on Oct 12, 2026, −46.0% over the past year.
Is Artivion stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and seasonality) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Artivion the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.